Clinical Trial

Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

Study acronym: NEXT-REGIRI
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and Lonsurf) no longer have treatment options available while maintaining a good performance status which would allow them to receive a new treatment
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2019-02-01; most recent amendment 2025-11-14.
Status change: Recruiting → Active, Not Recruiting 2024-09-19
Status change: Not Yet Recruiting → Recruiting 2019-04-05
Trial Details
NCT Number NCT03829462
Lead Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Conditions Metastatic Colorectal Cancer (mCRC)
Enrollment 377 participants
Start Date 2019-03-28
Primary Completion 2024-09-04 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-21